Rachele Alzani
Publications by Year
Research Areas
Microtubule and mitosis dynamics, Cancer-related Molecular Pathways, Monoclonal and Polyclonal Antibodies Research, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research
Most-Cited Works
- → Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer(2015)245 cited
- → A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity(2008)213 cited
- → The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition(2014)152 cited
- → NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies(2012)119 cited
- → 3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization(2005)108 cited
- → Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.(2009)103 cited
- → Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms(2014)68 cited
- → Suramin induces deoligomerization of human tumor necrosis factor alpha(1993)65 cited
- → Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing(2010)62 cited
- Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.(2010)